US equities |
NVDA $238.76 ▲+2.06% SPCX $167.94 ▲+5.65% MU $1,060.32 ▼-1.36% TSLA $380.55 ▲+2.69% MSFT $527.06 ▲+1.84% SNDK $1,692.34 ▼-1.61% INTC $116.66 ▼-2.24% META $742.70 ▲+2.01%
FinancialContent

Bio-Path Holdings, Inc. - Common Stock (NQ:BPTH)

0.2100 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Path Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Life Sciences Investor Forum: Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for June 11th-12th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path... 
Via Newsfile
Topics Intellectual Property
News headline image
Bio-Path Holdings Provides Clinical and Operational Update
Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential Licensing Opportunities 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
Bio-Path Holdings Reports Full Year 2024 Financial Results
Reports Continued Progress Across Both Obesity and Oncology Franchises 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Which stocks are moving on Tuesday? ↗
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Tuesday's session: gap up and gap down stocks ↗
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
US Stocks Mixed; NY State Business Activity Rises In February ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's pre-market session? ↗
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Bio-Path Holdings Expands Global Patent Portfolio
Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
Bio-Path Holdings Provides Key Clinical Updates
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
Wondering what's happening in today's after-hours session? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
Bio-Path Holdings Provides 2025 Clinical and Operational Update
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline ↗
 
Via Benzinga
News headline image
Bio-Path Holdings Shares Were On The Rise: What's Going On? ↗
Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares are surging Thursday following the company's announcement of encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2... 
Via Benzinga
News headline image
Gold Falls Sharply, Lamb Weston Shares Plunge ↗
 
Via Benzinga
News headline image
US Stocks Higher, Micron Reports Downbeat Sales ↗
 
Via Benzinga
News headline image
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 Diabetes 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24
Dallas, Texas--(Newsfile Corp. - December 13, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path... 
Via Newsfile
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
From Bio-Path Holdings, Inc.
Via GlobeNewswire
News headline image
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >